Literature DB >> 18723515

A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand.

Celine Valant1, Karen J Gregory, Nathan E Hall, Peter J Scammells, Michael J Lew, Patrick M Sexton, Arthur Christopoulos.   

Abstract

Many G protein-coupled receptors (GPCRs) possess allosteric binding sites distinct from the orthosteric site utilized by their cognate ligands, but most GPCR allosteric modulators reported to date lack signaling efficacy in their own right. McN-A-343 (4-(N-(3-chlorophenyl)carbamoyloxy)-2-butynyltrimethylammonium chloride) is a functionally selective muscarinic acetylcholine receptor (mAChR) partial agonist that can also interact allosterically at the M(2) mAChR. We hypothesized that this molecule simultaneously utilizes both an allosteric and the orthosteric site on the M(2) mAChR to mediate these effects. By synthesizing progressively truncated McN-A-343 derivatives, we identified two, which minimally contain 3-chlorophenylcarbamate, as pure allosteric modulators. These compounds were positive modulators of the orthosteric antagonist N-[(3)H]methylscopolamine, but in functional assays of M(2) mAChR-mediated ERK1/2 phosphorylation and guanosine 5'-3-O-([(35)S]thio)triphosphate binding, they were negative modulators of agonist efficacy. This negative allosteric effect was diminished upon mutation of Y177A in the second extracellular (E2) loop of the M(2) mAChR that is known to reduce prototypical allosteric modulator potency. Our results are consistent with McN-A-343 being a bitopic orthosteric/allosteric ligand with the allosteric moiety engendering partial agonism and functional selectivity. This finding suggests a novel and largely unappreciated mechanism of "directed efficacy" whereby functional selectivity may be engendered in a GPCR by utilizing an allosteric ligand to direct the signaling of an orthosteric ligand encoded within the same molecule.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18723515      PMCID: PMC2662018          DOI: 10.1074/jbc.M803801200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

Review 1.  Qualitative and quantitative assessment of relative agonist efficacy.

Authors:  A Christopoulos; E E El-Fakahany
Journal:  Biochem Pharmacol       Date:  1999-09-01       Impact factor: 5.858

Review 2.  Functional selectivity and classical concepts of quantitative pharmacology.

Authors:  Jonathan D Urban; William P Clarke; Mark von Zastrow; David E Nichols; Brian Kobilka; Harel Weinstein; Jonathan A Javitch; Bryan L Roth; Arthur Christopoulos; Patrick M Sexton; Keith J Miller; Michael Spedding; Richard B Mailman
Journal:  J Pharmacol Exp Ther       Date:  2006-06-27       Impact factor: 4.030

Review 3.  Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox.

Authors:  Christopher J Langmead; Arthur Christopoulos
Journal:  Trends Pharmacol Sci       Date:  2006-08-04       Impact factor: 14.819

Review 4.  Allosteric modulation of G protein-coupled receptors.

Authors:  Lauren T May; Katie Leach; Patrick M Sexton; Arthur Christopoulos
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

5.  Probing the beta2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists.

Authors:  Gayathri Swaminath; Xavier Deupi; Tae Weon Lee; Wen Zhu; Foon Sun Thian; Tong Sun Kobilka; Brian Kobilka
Journal:  J Biol Chem       Date:  2005-04-07       Impact factor: 5.157

6.  Allosteric binding sites on muscarinic acetylcholine receptors.

Authors:  Jürgen Wess
Journal:  Mol Pharmacol       Date:  2005-09-23       Impact factor: 4.436

7.  Site-directed mutagenesis of the putative human muscarinic M2 receptor binding site.

Authors:  F Heitz; J A Holzwarth; J P Gies; R M Pruss; S Trumpp-Kallmeyer; M F Hibert; C Guenet
Journal:  Eur J Pharmacol       Date:  1999-09-10       Impact factor: 4.432

8.  Estimation of agonist activity at G protein-coupled receptors: analysis of M2 muscarinic receptor signaling through Gi/o,Gs, and G15.

Authors:  Michael T Griffin; Katherine W Figueroa; Sarah Liller; Frederick J Ehlert
Journal:  J Pharmacol Exp Ther       Date:  2007-03-28       Impact factor: 4.030

Review 9.  Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology.

Authors:  Katie Leach; Patrick M Sexton; Arthur Christopoulos
Journal:  Trends Pharmacol Sci       Date:  2007-07-13       Impact factor: 14.819

10.  Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors.

Authors:  Lauren T May; Vimesh A Avlani; Christopher J Langmead; Hugh J Herdon; Martyn D Wood; Patrick M Sexton; Arthur Christopoulos
Journal:  Mol Pharmacol       Date:  2007-05-24       Impact factor: 4.436

View more
  57 in total

1.  Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery.

Authors:  Bruce J Melancon; Corey R Hopkins; Michael R Wood; Kyle A Emmitte; Colleen M Niswender; Arthur Christopoulos; P Jeffrey Conn; Craig W Lindsley
Journal:  J Med Chem       Date:  2012-01-06       Impact factor: 7.446

2.  Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms.

Authors:  Vindhya Nawaratne; Katie Leach; Christian C Felder; Patrick M Sexton; Arthur Christopoulos
Journal:  J Biol Chem       Date:  2010-04-20       Impact factor: 5.157

Review 3.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 4.  Targeting glutamate synapses in schizophrenia.

Authors:  Julie R Field; Adam G Walker; P Jeffrey Conn
Journal:  Trends Mol Med       Date:  2011-09-28       Impact factor: 11.951

5.  Mutagenesis of nucleophilic residues near the orthosteric binding pocket of M1 and M2 muscarinic receptors: effect on the binding of nitrogen mustard analogs of acetylcholine and McN-A-343.

Authors:  Hinako Suga; Gregory W Sawyer; Frederick J Ehlert
Journal:  Mol Pharmacol       Date:  2010-07-19       Impact factor: 4.436

6.  A muscarinic view on Gq.

Authors:  Klaus Mohr; Christian Tränkle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-11       Impact factor: 3.000

Review 7.  Emerging paradigms in GPCR allostery: implications for drug discovery.

Authors:  Denise Wootten; Arthur Christopoulos; Patrick M Sexton
Journal:  Nat Rev Drug Discov       Date:  2013-08       Impact factor: 84.694

8.  Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias.

Authors:  Karen J Gregory; Nathan E Hall; Andrew B Tobin; Patrick M Sexton; Arthur Christopoulos
Journal:  J Biol Chem       Date:  2010-01-05       Impact factor: 5.157

9.  Chemical modification of the M(1) agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding mode.

Authors:  Gregory J Digby; Thomas J Utley; Atin Lamsal; Christian Sevel; Douglas J Sheffler; Evan P Lebois; Thomas M Bridges; Michael R Wood; Colleen M Niswender; Craig W Lindsley; P Jeffrey Conn
Journal:  ACS Chem Neurosci       Date:  2012-09-09       Impact factor: 4.418

10.  Agonists with supraphysiological efficacy at the muscarinic M2 ACh receptor.

Authors:  R Schrage; W K Seemann; J Klöckner; C Dallanoce; K Racké; E Kostenis; M De Amici; U Holzgrabe; K Mohr
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.